Pieter Slegers — Is L'Oréal an interesting stock? (Compounding Quality)

One-line take: the archive's cleanest example of a pass on growth rather than on price — and the one where the two objections point in opposite directions. The quality case is strong and largely unqualified: L'Oréal is "the number 1 beauty company worldwide" with a 14.5% market share, 37 brands in 150 countries, a 74.3% gross margin, a capital-light model (CAPEX/sales 3.4%), FCF at 116.9% of net income, almost no stock-based compensation (4.8% of net income, 3.8% on a five-year average) and the best governance story in the archive — six CEOs in 115 years, an average tenure of 19 years against an 8.1-year norm, and Françoise Bettencourt still owning 29.5%. Total Quality Score 7.8/10, the same score FICO would later receive. Then the two failures that decide it. ROIC is 13.9% and ROE 18.0% — both below the house thresholds of 15% and 20%, on a business usually described as a brand machine. And the growth is not there: the forward PE of 27.0x against a 31.5x ten-year average passes the first valuation test, but the earnings-growth model returns only 8.0% a year and the reverse DCF demands 13.0% annual FCF growth against 8.7% delivered over a decade. The verdict names its own price: "L'Oréal is a wonderful business but the future growth prospects are too low. I would love to own L'Oréal at 20x earnings… a price of €271 (current stock price: €367.4)" — a 26% discount. Note the honesty of the moat section: L'Oréal "spends roughly 32% of its revenue on advertising and promotion expenses. It makes you wonder what is doing the heavy lifting: the brand or the advertising?" — a question the write-up poses and does not answer, and the sharpest challenge to a consumer-brand moat anywhere in this archive.

1. Stocks & names mentioned

One subject company, scored on the 15-step worksheet; the three named peers and the retail channel appear as the competitive and distribution context. Research legend: QT Qualtrim · SA Seeking Alpha · STK Stock Analysis. Written post with no timestamps — the At link opens the article.

Ticker	Name	Research	View	What he said	At
OR.PA	L'Oréal S.A.	QT · SA · STK	Neutral	A published pass with a named entry price: "L'Oréal is a wonderful business but the future growth prospects are too low. I would love to own L'Oréal at 20x earnings… a price of €271 (current stock price: €367.4)." Classified as an Owner-Operator; Total Quality Score 7.8/10 at €184.8bn. The strengths: number one worldwide with a 14.5% market share, 37 brands in 150 countries, four segments (Consumer 36.5%, Luxe 35.4%, Dermatological 16.4%, Professional 11.7%), gross margin 74.3%, net margin 13.9%, FCF/net income 116.9%, CAPEX/sales 3.4%, interest coverage 24.3x, SBC 4.8% of net income, and governance scored 9/10 — six CEOs in 115 years (19-year average tenure vs an 8.1-year norm), CEO Nicolas Hieronimus with €87.2m of stock and Françoise Bettencourt on 29.5%. The failures are recorded rather than argued away: ROIC 13.9% (<15% ❌), ROE 18.0% (<20% ❌), goodwill/assets 23.4% (>20% ❌), ten-year owner's-earnings CAGR 9.1% (<12% ❌) and a CAGR since 2001 of 8.2% (<12% ❌). Valuation splits: forward PE 27.0x vs a 31.5x ten-year average ✅, but the earnings-growth model returns 8.0% ("we target a higher expected return") and the reverse DCF implies 13.0% FCF growth against 8.7% delivered ❌. "There are more attractive companies today if you ask me."	read ↗
EL	The Estée Lauder Companies	QT · SA · STK · FA	Neutral	Named twice as context, not as a candidate: first in the risk list — "intense competition from rivals like Estée Lauder, Procter & Gamble, and Unilever" — and again on the onepager as one of L'Oréal's three "main peers". The only colour offered is a quote attributed to Leonard Lauder, "the son of Estée Lauder": "Think in decades, not quarters." No analysis or stance on the shares.	read ↗
PG	Procter & Gamble	QT · SA · STK · FA	Neutral	Named only as a rival in the risk section and as a "main peer" on the onepager — "intense competition from rivals like Estée Lauder, Procter & Gamble, and Unilever". No stance. Worth reading against the Lindy series five months later, where P&G's moat is argued to be the same one dismissed here as advertising-funded: "small, frequent, habitual purchases plus a scale of advertising and shelf space no entrant can match."	read ↗
ULVR.L	Unilever PLC	QT · SA · STK	Neutral	The third named rival and third "main peer" on the onepager — "intense competition from rivals like Estée Lauder, Procter & Gamble, and Unilever". The archive's first mention of the company; no analysis, no stance.	read ↗
ULTA	Ulta Beauty	QT · SA · STK · FA	Neutral	Named once, as a distribution channel rather than an investment: L'Oréal's Consumer Products are found "in stores like Sephora or Ulta Beauty". Notable only because Ulta is one of Compounding Quality's two disclosed sells since 2023 — sold after concluding US beauty retail was more competitive and fragmented than modelled, which is the same fragmentation named here as a risk to L'Oréal ("rising threat from niche beauty brands"). No stance is offered in this post.	read ↗

Three notes. (1) The pass is on growth, not on price. Unlike the FICO, HEICO and Cintas passes — all of which turn on a multiple — L'Oréal clears the first valuation test (27.0x against a 31.5x ten-year average) and is still declined, because the earnings-growth model and the reverse DCF both fail. The stated reason is explicit: "the future growth prospects are too low." (2) The advertising question is left open. "Year after year, L'Oréal spends roughly 32% of its revenue on advertising and promotion expenses. It makes you wonder what is doing the heavy lifting: the brand or the advertising?" — the write-up raises the possibility that the moat is rented rather than owned, then scores the moat 8.5/10 anyway. (3) Licensed luxury brands are named but not analysed. The Luxe segment (35.4% of revenue) runs on licences with Giorgio Armani and Prada; neither the licence terms nor the renewal risk is discussed, which is the segment's central question.

2. Talking points

The business in four segments

"L'Oréal sells beauty and confidence with their iconic products. And they do it through 37 brands in 150 countries" — Maybelline New York, Garnier, Lancôme and L'Oréal Paris are the ones shown.
Segment split: Consumer Products 36.5% (sold through Sephora, Ulta and similar), L'Oréal Luxe 35.4% (licences with Giorgio Armani and Prada), Dermatological Beauty 16.4% (medical-grade skincare), Professional Products 11.7% (direct to hairstylists).
Geographically even too: Europe 30.8%, North Asia 28.0%, North America 26.7%, Latin America 5.9%, others 8.6% — "L'Oréal is very well diversified in all aspects."

Governance is the strongest section, and it scores highest

"Do you know the average tenure of a CEO? It's 8.1 years. L'Oréal does it differently. In its long history of 115 (!) years, they only had 6 CEOs. That's 19 years on average per CEO."
Current CEO Nicolas Hieronimus joined in 1987 and owns €87.2 million of stock; Françoise Bettencourt, the founder's granddaughter, still holds over 29.5% and sits on the board.
Scored 9/10, the highest mark on the card, and the reason the company is filed under Owner-Operator — one of the three house buckets alongside monopolies/oligopolies and cannibal stocks.

The advertising question

"L'Oréal has very strong brands. People spot their products right away on the store shelves. However, there's an important nuance there."
"Year after year, L'Oréal spends roughly 32% of its revenue on advertising and promotion expenses. It makes you wonder what is doing the heavy lifting: the brand or the advertising?"
The moat is then defended on scale rather than brand — the "piranhas" are barriers to scale ("it takes decades to come to the scale that's relevant"), the "crocodiles" are unit-cost advantages.

Two hard thresholds missed

ROIC 13.9% against the >15% rule and ROE 18.0% against >20% — both marked ❌. "In an ideal world, we would prefer these numbers to be a little bit higher."
Goodwill/assets 23.4% against the <20% rule — "in an ideal world, we would love to see less goodwill." A quiet signal that some of the brand portfolio was bought rather than built.
Everything else on the balance sheet passes comfortably: interest coverage 24.3x, net debt/FCF 0.3x.

Quality that is genuinely capital-light

CAPEX/sales 3.4% and CAPEX/operating cash flow 19.6% — "L'Oréal has a capital light business model… it can take a large part of Free Cash Flow to invest in growth or to distribute to shareholders."
Gross margin 74.3%, net margin 13.9%, and FCF at 116.9% of net income — cash conversion above 100%, the metric the house framework insists on ("earnings are an opinion, cash flow is a fact").
SBC is a non-issue: 4.8% of net income today, 3.8% on a five-year average — the opposite of the FICO case, where a 22% SBC bill decided the answer.

The end market: mature, but not disruptable

Three tailwinds named: an ageing population needing more beauty products, a rising Asian middle class with "600 million potential new customer by 2030", and skincare as a global growth category. The overall market is projected to grow 6.7% a year to 2030.
"Even though L'Oréal isn't active in a fast-growing industry, the risk of disruption is pretty low. A great company stays great for a long time."
The supporting quote is the Bezos inversion: "I very frequently get the question: 'What's going to change in the next 10 years?' And I almost never get the question: 'What's not going to change in the next 10 years?'"

The five risks, in the author's order

The law of large numbers first: "with around $51.7 billion in annual sales, L'Oréal's size makes rapid growth more challenging" — which is also the reason the pass is written.
Competition from Estée Lauder, P&G and Unilever; and separately from niche brands taking share.
Digitalisation as a moat-eroder: smaller competitors "don't have to battle for expensive shelf space anymore" — the specific mechanism by which the scale advantage stops working. Scored 6.5/10, the lowest mark on the card.

Growth: good history, thin forecast

History passes on every line: revenue +9.5% (5yr) and +6.1% (10yr); EPS +12.5% (5yr) and +7.1% (10yr).
The forecast is the problem: expected revenue growth of 5.0% over two years and a long-term EPS estimate of 7.0% — exactly at the threshold, not above it. "In an ideal world, we would love to see the revenue growth a bit higher."
Realised shareholder returns are weaker still: +3.2% five-year CAGR and +8.2% since 2001, both under the 12% bar.

Three valuations that disagree

Forward PE 27.0x against a 31.5x ten-year average — a pass, and "the valuation of L'Oréal came down significantly since 2022."
Earnings-growth model: 7.0% EPS growth + 1.7% dividend yield + a multiple decline from 27.0x to 25.0x = 8.0% a year. "An expected yearly return of 8.0% is good, but we target a higher expected return in general."
Reverse DCF, built from €7,350.0m of expected FCF less €248.0m of SBC plus €54.0m of growth capex = €7,156.0m in year one, implying 13.0% annual FCF growth for ten years against 8.7% delivered over the last ten. Two of three methods fail, and the two that fail are the forward-looking ones.

The verdict, and the price attached to it

"L'Oréal is a wonderful business but the future growth prospects are too low. I would love to own L'Oréal at 20x earnings. This means I would love to buy L'Oréal at a price of €271 (current stock price: €367.4)."
That is a required fall of about 26%, and a multiple below the level at which any other pass in this archive has been set — 20x against Cintas' 25x and FICO's 25x-after-SBC.
The closing line is a redirect rather than a hedge: "There are more attractive companies today if you ask me. Which ones? The ones in Our Portfolio!"

3. In plain English

A jargon-free summary of the thesis behind each argued name. (Renders on each name's consolidated page.)

OR.PA — L'Oréal S.A. Neutral

L'Oréal is the biggest beauty company in the world. It owns about 37 brands — Maybelline, Garnier, Lancôme, L'Oréal Paris — sells them in 150 countries, and takes roughly one in every seven euros spent on beauty products globally. Making shampoo and lipstick costs very little relative to what people pay for it, so about three-quarters of every euro of sales is left after the cost of the product itself.

It is also unusually well run for a company this old. In 115 years it has had six chief executives — an average of nineteen years each, against about eight years for a typical company — and the founder's granddaughter still owns almost 30% of it and sits on the board. Owners who cannot easily leave tend to think in decades, and that is the single highest score this write-up gives the company.

The business also barely needs money to run. It spends only about 3% of sales on equipment and buildings, and it turns more cash into shareholders' hands than it reports as profit. It hands out almost no free shares to staff, which is a real cost at many companies and almost none here.

So why is it not bought? Because it is too big to grow fast, and the shares are priced as if it will. Sales are already around $52 billion a year, and the analysts' own forecast is for revenue to grow about 5% a year. Working backwards from today's share price, buyers are effectively assuming the company's spare cash grows 13% a year for the next decade — a rate it has never come close to, having managed about 8.7% over the last ten years.

Two other things are quietly wrong. The return the company earns on the money invested in it (about 14%) is below the standard this framework insists on (15%), and a fifth of its assets are goodwill — the premium paid for brands it bought rather than built. And the moat itself gets an honest question rather than an answer: L'Oréal spends about a third of its revenue on advertising, which raises the possibility that the brand's strength is being rented every year rather than owned outright.

The conclusion is a wonderful business at the wrong price, with the right price stated: 20 times earnings, or €271 a share. It costs €367.40 today.

Summary derived from the archived Compounding Quality post (text in transcript.txt) for personal study. Not investment advice. © Compounding Quality / Pieter Slegers for source material.